BIOCYTOGEN PHARMA. H YC1 Cash Flow Quality Index
BIOCYTOGEN PHARMA. H YC1 cash flow quality index. BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow Quality Index of 2.14x as of December 2025. Operating cash flow of €370.25 Million exceeds net income of €173.20 Million, indicating high earnings quality where cash backs reported profits. See I54 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Cash flow quality index of BIOCYTOGEN PHARMA. H YC1 from 2024 to 2025. Historical Cash Flow Quality Index for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BIOCYTOGEN PHARMA. H YC1 (I54) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
BIOCYTOGEN PHARMA. H YC1 Cash Flow Quality Index by Year (2024–2025)
BIOCYTOGEN PHARMA. H YC1 cash flow quality index by year from 2024 to 2025. Year-by-year earnings quality comparison for BIOCYTOGEN PHARMA. H YC1. For the full cash flow conversion analysis, see BIOCYTOGEN PHARMA. H YC1 (I54) cash conversion ratio.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.14x | €370.25 Million | €173.20 Million | ▼ -66.1% |
| 2024 | 6.30x | €211.25 Million | €33.54 Million | — |